Rohto Q4 Profit Up, Asia Sales Drive Growth

Key Performance Highlights

Rohto Pharmaceutical announced a fourth-quarter operating income of 7.5 billion yen, surpassing analyst forecasts by 4.1% but falling below the market consensus estimate of 8.4 billion yen. The company demonstrated solid top-line performance with consolidated sales increasing 9.6% year-over-year, while operating profit grew by 8.1%.

Regional and Brand Performance

The company's growth was significantly driven by strong performance across its Asian markets. Sales in Indonesia and Vietnam recorded high-teen and mid-teen growth, respectively. This momentum was supported by key brands, with Hada Labo sales growing 14% and Obagi increasing 16.2% during the quarter. The improved sales contributed to a better cost of goods sold ratio due to higher factory utilization rates.

Outlook and Corporate Actions

Looking forward to fiscal year 2027, Rohto has issued guidance projecting 7.5% sales growth and a 6.5% increase in operating profit. Alongside its positive earnings report, the company also declared a dividend increase for its shareholders. A detailed briefing on the results and future strategy is scheduled for Thursday.

Summary and Next Steps

Rohto's Q4 results highlight robust regional growth, particularly in Southeast Asia, which helped navigate a mixed profit outcome against market expectations. Investors will look to the upcoming company briefing for further details on its strategic plans and long-term growth drivers.

FAQ

Q: What was Rohto's reported Q4 operating income?
A: Rohto reported a fourth-quarter operating income of 7.5 billion yen.

Q: Which regions showed the strongest sales growth for Rohto?
A: Indonesia and Vietnam were the strongest performing regions, posting high-teen and mid-teen growth rates, respectively.

Source: Investing.com